Compare Harley-Davidson Inc (HOG) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Harley-Davidson Inc trades at $26.92 (market cap $2.86B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2.6× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.73% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 92 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HOG | SYRE | |
|---|---|---|
Market Cap | $2.86B | $7.52B |
Volume | 1,391,703 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $28.46 | $108.92 |
52-Week Low | $17.19 | $22.18 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $3.27B | $6.52B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.96, down 1.5% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 EPS beat ($0.75 actual vs. $0.645 expected) but missed in Q4 2025 and Q1 2026. Revenue has declined from $5.8B in 2022 to $4.5B in 2025, with net income margin falling to 4.78%. Recent news highlights tariff risks and a data breach investigation, while analyst consensus is a $28.50 price target with a Hold-heavy rating.
The outlook is cautious; HOG faces revenue pressure and margin compression, offset by low valuation multiples (P/E 15.26, P/S 0.74) and a dividend. Key risks include competitive threats, tariff exposure, and economic sensitivity. Upside depends on execution of the 'Back to the Bricks' plan stabilizing sales, but investor sentiment remains neutral amid institutional selling and mixed earnings trends.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
